STOCK TITAN

Mereo Biopharma - MREO STOCK NEWS

Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.

Mereo Biopharma Group plc (MREO) is a clinical-stage biopharmaceutical leader developing innovative treatments for rare diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical progress, strategic partnerships, and regulatory developments.

Our curated collection features official press releases and verified news covering critical milestones including clinical trial results, regulatory submissions, and strategic collaborations. Track updates across Mereo's pipeline targeting conditions like osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

All content undergoes rigorous verification to ensure accuracy and relevance. For comprehensive tracking of Mereo's progress in rare disease therapeutics, bookmark this page for direct access to primary source materials and expert analysis of corporate developments.

Rhea-AI Summary

Mereo BioPharma reported its Q1 2024 financial results, showing cash and cash equivalents of $48.7 million. The company expects to fund operations into 2026. Key updates include the completion of enrollment in the Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta by partner Ultragenyx, and ongoing pre-launch activities in Europe. Mereo also announced progress in partnering discussions and research for alvelestat and etigilimab. Financial highlights included a 25% decrease in R&D expenses, a 8% reduction in general and administrative expenses, and a net loss of $9.0 million, compared to $12.1 million in Q1 2023. The company remains focused on advancing its clinical programs and engaging with partners for future developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
-
Rhea-AI Summary
Mereo BioPharma Group plc (MREO) announced CEO Dr. Denise Scots-Knight will participate in a Fireside Chat at the Needham Virtual Healthcare Conference. The presentation will be on April 9, 2024, at 10:15am ET / 03:15pm BST, with a live webcast accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
Rhea-AI Summary
Mereo BioPharma Group plc announced financial results for 2023, highlighting progress in Phase 2/3 Orbit and Phase 3 Cosmic studies of setrusumab in Osteogenesis Imperfecta. Partnering discussions for alvelestat are advancing, with cash of $57.4 million as of December 31, 2023, expected to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
Rhea-AI Summary
Mereo BioPharma Group plc (NASDAQ: MREO) announced that Dr. Denise Scots-Knight, CEO, will participate in a Fireside Chat at Leerink Partners Global Biopharma Conference. The live webcast can be accessed on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
-
Rhea-AI Summary
Mereo BioPharma Group plc (MREO) expects to complete enrollment in the Phase 3 portion of the Orbit Study and Phase 3 Cosmic Study for Osteogenesis Imperfecta treatment by partner Ultragenyx by 1Q 2024 and 1H 2024, respectively. The company also signed a global licensing deal for leflutrozole and reiterated its cash runway guidance into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
-
Rhea-AI Summary
Mereo BioPharma Group plc provides an update on recent program developments and third quarter 2023 financial information. Setrusumab achieves a 67% reduction in annualized fracture rate in patients with osteogenesis imperfecta. Alvelestat shows significant effects on lung disease. Etigilimab shows promising efficacy in solid tumors. The Company has cash and short-term deposits of £51.2 million ($62.4 million) as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
Rhea-AI Summary
Mereo BioPharma CEO to participate in Fireside Chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
conferences
-
Rhea-AI Summary
Mereo BioPharma announces unaudited interim financial results for H1 2023 and provides update on recent corporate highlights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences
Rhea-AI Summary
Mereo BioPharma presents data from Phase 2 trial of alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease at ATS2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
Mereo Biopharma

Nasdaq:MREO

MREO Rankings

MREO Stock Data

338.67M
148.48M
1.02%
74.31%
4.1%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON